aripiprazole has been researched along with aripiprazole lauroxil in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (72.73) | 24.3611 |
| 2020's | 9 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Bose, A; Citrome, L; Claxton, A; Du, Y; Ehrich, EW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J | 1 |
| Citrome, L | 2 |
| Aggarwal, A; Gopalakrishna, G; Lauriello, J | 1 |
| Bose, A; Du, Y; Ehrich, EW; Nasrallah, HA; Newcomer, JW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J | 1 |
| Du, Y; Jamal, HH; Pendergrass, JC; Risinger, R; Silverman, BL; Targum, SD | 1 |
| Bose, A; Du, Y; Ehrich, E; Potkin, SG; Risinger, R; Silverman, B; Stankovic, S; Zummo, J | 1 |
| Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ | 1 |
| Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ | 1 |
| Citrome, L; Cutler, AJ; Du, Y; Nasrallah, HA; Risinger, R; Silverman, BL; Zummo, J | 1 |
| Hard, M; Risinger, R; Weiden, PJ | 1 |
| Aquila, R; Jamal, HH; Nasrallah, HA; Risinger, R; Stanford, AD; Weiden, PJ | 1 |
| Frampton, JE | 1 |
| Cameron, C; Desai, D; Drake, C; Hutton, B; Kotb, A; Weiden, PJ; Zummo, J | 1 |
| Gai, Y; Leng, G; Liu, W; Lu, X; Sha, C; Sun, Y; Yang, X | 1 |
| Du, Y; Liu, CC; Stanford, AD; Weiden, PJ | 1 |
| Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY | 1 |
| Li, GF; Wu, JY; Yu, G | 1 |
| Du, Y; Hard, ML; von Moltke, L; Walling, D; Wehr, AY; Weiden, PJ | 1 |
| Aquila, R; Claxton, A; Du, Y; Nasrallah, HA; Stanford, AD; Weiden, PJ | 1 |
| Claxton, A; Du, Y; Miller, BJ; Potkin, SG; Weiden, PJ | 1 |
| Claxton, A; Correll, CU; Du, Y; Stanford, AD; Weiden, PJ | 1 |
| Faldu, SP; Farwick, S; Hickey, MB; Jacobs, G; Vandiver, J; Weiden, PJ | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Bidollari, I; Cash, E; Claxton, A; Du, Y; Keane, E; Kunovac, J; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B | 1 |
| Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ | 1 |
| Claxton, A; Du, Y; Lauriello, J; Weiden, PJ | 1 |
| Du, Y; Faldu, S; Rege, B; Sommi, RW; Wehr, A; Weiden, PJ | 1 |
| Lysaker, PH; McEvoy, JP; O'Sullivan, AK; Sun, X; Weiden, PJ | 1 |
| Bidollari, I; Claxton, A; Du, Y; Kelly, DL | 1 |
| Boulanger, L; Gleeson, CD; Hedgeman, E; Jariwala-Parikh, K; Lauriello, J; O'Sullivan, AK; Shah, A; Weiden, PJ | 1 |
| Claxton, A; Du, Y; Nasrallah, HA; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B | 1 |
7 review(s) available for aripiprazole and aripiprazole lauroxil
| Article | Year |
|---|---|
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Injections; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2016 |
Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Psychotic Disorders; Schizophrenia; United States | 2016 |
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine | 2016 |
Aripiprazole Lauroxil: A Review in Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Injections, Intramuscular; Recurrence; Schizophrenia | 2017 |
Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bayes Theorem; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Network Meta-Analysis; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2018 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular | 2022 |
16 trial(s) available for aripiprazole and aripiprazole lauroxil
| Article | Year |
|---|---|
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asia; Disease Progression; Europe; Female; Hostility; Humans; Injections, Intramuscular; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Agitation; Recurrence; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aripiprazole; Blood Glucose; Body Weight; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Injections, Intramuscular; Lipids; Lipoproteins; Male; Middle Aged; Prolactin; Risk; Schizophrenia; Schizophrenic Psychology; Young Adult | 2016 |
Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Sex Factors; Young Adult | 2017 |
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2017 |
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Models, Biological; Psychotic Disorders; Schizophrenia | 2017 |
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Schizophrenia | 2018 |
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outcome Assessment, Health Care; Schizophrenia | 2017 |
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol; Delayed-Action Preparations; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Injections, Intramuscular; Male; Middle Aged; Outpatients; Prolactin; Schizophrenia; Triglycerides; Weight Gain; Young Adult | 2017 |
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Injections; Long Term Adverse Effects; Male; Middle Aged; Schizophrenia | 2019 |
Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Schizophrenia; Treatment Outcome | 2018 |
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Drug Tolerance; Female; Humans; Long Term Adverse Effects; Male; Middle Aged; Schizophrenia | 2019 |
Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Social Behavior; Time Factors; Treatment Outcome; Young Adult | 2019 |
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Hospitalization; Humans; Injections, Intramuscular; Middle Aged; Paliperidone Palmitate; Patient Discharge; Schizophrenia; Young Adult | 2020 |
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2020 |
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2020 |
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Patient Reported Outcome Measures; Quality of Life; Schizophrenia; Treatment Outcome | 2021 |
10 other study(ies) available for aripiprazole and aripiprazole lauroxil
| Article | Year |
|---|---|
Two long-acting injectable antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Injections; Paliperidone Palmitate; Schizophrenia; United States; United States Food and Drug Administration | 2015 |
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Injections, Intramuscular; Models, Theoretical; Schizophrenia | 2017 |
LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies.
Topics: Animals; Aripiprazole; Biotransformation; Chromatography, Liquid; Linear Models; Male; Prodrugs; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Computer Simulation; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Models, Biological; Nanoparticles | 2018 |
Model-Informed Approaches for Alternative Aripiprazole Dosing Regimens and Missed Dose Management: Towards Better Adherence to Antipsychotic Pharmacotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule | 2018 |
Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Prospective Studies; Schizophrenia | 2019 |
Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Compounding; Humans; Injections; Practice Guidelines as Topic | 2019 |
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia.
Topics: Adult; Aripiprazole; Diabetes Mellitus, Type 2; Humans; Quality of Life; Schizophrenia | 2021 |
Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Paliperidone Palmitate; Prolactin; Prospective Studies; Schizophrenia | 2021 |
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Delayed-Action Preparations; Drug Costs; Female; Humans; Injections; Longitudinal Studies; Male; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult | 2021 |